4 results match your criteria: "and Osaka City University Graduate School of Medicine[Affiliation]"
Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial.
Arthritis Care Res (Hoboken)
March 2022
Ruhr-University Bochum, Bochum, Germany, and Osaka City University Graduate School of Medicine, Osaka, Japan.
Article Synopsis
- The COAST-X trial assessed the impact of ixekizumab on functioning and health in patients with active nonradiographic axial spondyloarthritis over 52 weeks, comparing it to placebo.
- Ixekizumab treatment led to significant improvements in self-reported health scores, particularly in physical functioning, pain, and overall health status, with better results in patients receiving treatment every 2 weeks.
- Patients on ixekizumab reported notable enhancements in quality of life measures (EQ-5D-5L) compared to placebo, showing sustained benefits by week 52.
Articular cartilage endurance and resistance to osteoarthritic changes require transcription factor Erg.
Arthritis Rheumatol
October 2015
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Objective: To determine whether and how the transcription factor Erg participates in the genesis, establishment, and maintenance of articular cartilage.
Methods: Floxed Erg mice were mated with Gdf5-Cre mice to generate conditional mutants lacking Erg in their joints. Joints of mutant and control mice were subjected to morphologic and molecular characterization and also to experimental surgically induced osteoarthritis (OA).
Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Diabetes Res Clin Pract
July 2012
Department of Metabolism, Endocrinology and Molecular Medicine, and Osaka City University Graduate School of Medicine, Osaka, Japan.
We evaluated the antialbuminuric advantage of cilnidipine, an N/L-type calcium channel blocker (CCB), compared with L-type CCBs in diabetic patients with normoalbuminuria and microalbuminuria. The study was a multicenter, non-randomized crossover trial. Participants were 90 type 2 diabetic patients exhibiting either normo- or microalbuminuria, and undergoing CCB treatment for ≥6 months prior to study entry.
View Article and Find Full Text PDF